pdufa.bio

ORZEYFUL (oveporexton)

Updated ยทnext FDA decision on the calendar

ORZEYFUL (oveporexton) The FDA approved it on Aug 5, 2026. 1 FDA decision on record below. Every date links its source.

TAK catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

PDUFA · Aug 5, 2026 ✓ ApprovedTAK

Questions

When is ORZEYFUL (oveporexton)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for ORZEYFUL (oveporexton); 1 FDA decision is on record below.

What happened at ORZEYFUL (oveporexton)'s most recent FDA decision?

On Aug 5, 2026 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

Has ORZEYFUL (oveporexton) been approved by the FDA?

Yes. The FDA approved an application for ORZEYFUL (oveporexton) on Aug 5, 2026; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.